A Phase 4 interventional study of Tadalafil in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 17 sites in China. Open to male participants aged 22 Years to 69 Years. Per ClinicalTrials.gov, last updated 2019-09-23.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 7th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2014, is one of 26 in phase 4, and was the 33rd registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 22 Years to 69 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 635 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 6th largest by enrollment, is the only one that started in 2014, is one of 12 in phase 4, and was the 28th registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of the study drug, taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED). The study will last about up to 25 months for each participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
Drug: Tadalafil
5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).
Drug: Tadalafil
Administered orally
Also known as: LY450190
Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)
A Treatment Emergent Adverse Event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline, regardless of causality or severity. The percentage of participants with TEAEs was calculated by dividing the number of participants with at least 1 TEAE over the 12-Month treatment period by the total number of participants analyzed, multiplied by 100%. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline through Month 12
Percentage of Participants Experiencing at Least One Adverse Event Leading to Discontinuation
Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs) that lead to discontinuation. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline through Month 12
Change From Baseline in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain Questionnaire Score
IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline\*visit, where participant is a random effect.
Time frame: Baseline, Month 1; Baseline, Month 3
Change From Baseline in the IIEF-EF Domain Questionnaire Score of 5 mg Tadalafil Treatments
IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline\*visit, where participant is a random effect.
Time frame: Baseline, Month 6; Baseline, Month 12;Baseline, Month 18; Baseline, Month 24
Percentage of Participants With "Yes" Responses to Sexual Encounter Profile (SEP) Diary
Participant-assessed diary has 5 questions(QI-Q5): 4 of the 5 questions were analyzed. Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period.
Time frame: Month 1, Month 3
Percentage of Participants Achieving Normal Erectile Functioning
Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of \>=26) at Month 1 and Month 3.
Time frame: Month 1, Month 3
Percentage of Participants Achieving Normal Erectile Functioning of 5 mg Tadalafil Treatments
Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of \>=26) at Month 6 and Month 12.
Time frame: Month 6, Month 12, Month 18, Month 24
Percentage of Participants With "Yes" Responses to Global Assessment Questions (GAQ)1 and GAQ2
Participants with "yes" responses to GAQ Question 1 (GAQ1) and GAQ Question 2 (GAQ2) of the GAQ questionnaire at Month 3 and Month 12. GAQ1: Has the treatment you have been taking during this study improved your erections? GAQ2: If yes, has the treatment improved your ability to engage in sexual activity?
Time frame: Month 3, Month12, Month 24
| Milestone | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Started | 211 | 424 |
| Received at least one dose of study drug | 210 | 421 |
| Completed | 192 | 388 |
| Not completed | 19 | 36 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 8 |
| Withdrew: Protocol violation | 4 | 8 |
| Withdrew: Withdrawal by subject | 8 | 18 |
| Withdrew: Sponsor decision | 2 | 1 |
| Milestone | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Started | 192 | 388 |
| Completed | 173 | 357 |
| Not completed | 19 | 31 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lost to follow-up | 3 | 5 |
| Withdrew: Protocol violation | 0 | 3 |
| Withdrew: Withdrawal by subject | 15 | 19 |
| Withdrew: Physician decision | 0 | 2 |
| Milestone | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Started | 173 | 357 |
| Completed | 131 | 283 |
| Not completed | 42 | 74 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 7 | 13 |
| Withdrew: Protocol violation | 4 | 11 |
| Withdrew: Withdrawal by subject | 25 | 43 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Sponsor decision | 2 | 1 |
A Treatment Emergent Adverse Event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline, regardless of causality or severity. The percentage of participants with TEAEs was calculated by dividing the number of participants with at least 1 TEAE over the 12-Month treatment period by the total number of participants analyzed, multiplied by 100%. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| Percentage of participants | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious) | 33.8 | 35.9 |
Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs) that lead to discontinuation. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| percentage of participants | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Percentage of Participants Experiencing at Least One Adverse Event Leading to Discontinuation | 1.4 | 0.7 |
IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline\*visit, where participant is a random effect.
| units on a scale | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Month 1 | 4.5 ± 0.42 | 6.2 ± 0.28 |
| Month 3 | 6.1 ± 0.44 | 7.4 ± 0.28 |
IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline\*visit, where participant is a random effect.
| units on a scale | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Month 6 | 8.2 ± 0.38 | 7.9 ± 0.27 |
| Month 12 | 8.1 ± 0.43 | 7.9 ± 0.27 |
| Month 18 | 8.6 ± 0.39 | 8.3 ± 0.27 |
| Month 24 | 8.6 ± 0.44 | 8.5 ± 0.28 |
Participant-assessed diary has 5 questions(QI-Q5): 4 of the 5 questions were analyzed. Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period.
| Percentage of participants | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Q2: successful penetration,Month 1 | 81.3 ± 34.58 | 86.7 ± 27.58 |
| Q2: successful penetration,Month 3 | 88.2 ± 28.55 | 91.7 ± 23.11 |
| Q3: successful intercourse,Month 1 | 41.2 ± 41.48 | 49.5 ± 42.85 |
| Q3: successful intercourse,Month 3 | 55.7 ± 43.19 | 60.1 ± 42.39 |
| Q4: satisfied with erection, Month 1 | 24.8 ± 35.62 | 35.5 ± 41.63 |
| Q4: satisfied with erection, Month 3 | 39.9 ± 43.73 | 43.5 ± 43.46 |
| Q5: satisfied with sexual experience,Month 1 | 20.4 ± 32.81 | 31.1 ± 40.50 |
| Q5: satisfied with sexual experience,Month 3 | 35.7 ± 41.93 | 39.2 ± 43.06 |
Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of \>=26) at Month 1 and Month 3.
| Percentage of partcipants | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Month 1 | 22.2 | 30.9 |
| Month 3 | 31.6 | 37.6 |
Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of \>=26) at Month 6 and Month 12.
| Percentage of participants | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Month 6 | 38.2 | 42.3 |
| Month 12 | 44.1 | 43.5 |
| Month 18 | 44.6 | 43.7 |
| Month 24 | 45.5 | 48.2 |
Participants with "yes" responses to GAQ Question 1 (GAQ1) and GAQ Question 2 (GAQ2) of the GAQ questionnaire at Month 3 and Month 12. GAQ1: Has the treatment you have been taking during this study improved your erections? GAQ2: If yes, has the treatment improved your ability to engage in sexual activity?
| percentage of participants | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Month 3: GAQ1 | 89.6 | 95.7 |
| Month 12: GAQ1 | 96.6 | 97.5 |
| Month 24: GAQ1 | 96.8 | 95.7 |
| Month 3: GAQ2 | 86.5 | 92.1 |
| Month 12: GAQ2 | 95.5 | 96.1 |
| Month 24: GAQ2 | 96.2 | 94.5 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2.5 mg/5 mg Tadalafil | — | 15/210 (7.1%) | 86/210 (41%) |
| 5 mg Tadalafil | — | 17/421 (4%) | 178/421 (42.3%) |
| Event | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Large intestine polypGastrointestinal disorders | 2/210 | 1/421 |
| Diabetes mellitusMetabolism and nutrition disorders | 2/210 | 0/421 |
| Myocardial infarctionCardiac disorders | 1/210 | 0/421 |
| MaculopathyEye disorders | 1/210 | 0/421 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 1/210 | 0/421 |
| CholelithiasisHepatobiliary disorders | 1/210 | 0/421 |
| Hepatic cystHepatobiliary disorders | 1/210 | 0/421 |
| PneumoniaInfections and infestations | 1/210 | 0/421 |
| Urethral stricture postoperativeInjury, poisoning and procedural complications | 1/210 | 0/421 |
| Ankylosing spondylitisMusculoskeletal and connective tissue disorders | 1/210 | 0/421 |
| Event | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 18/210 | 39/421 |
| Upper respiratory tract infectionInfections and infestations | 5/210 | 21/421 |
| ProstatitisReproductive system and breast disorders | 7/210 | 4/421 |
| HeadacheNervous system disorders | 2/210 | 13/421 |
| PeriodontitisInfections and infestations | 6/210 | 3/421 |
| Alanine aminotransferase increasedInvestigations | 5/210 | 1/421 |
| DizzinessNervous system disorders | 3/210 | 9/421 |
| Abdominal pain upperGastrointestinal disorders | 4/210 | 4/421 |
| Chronic gastritisGastrointestinal disorders | 4/210 | 3/421 |
| Blood uric acid increasedInvestigations | 4/210 | 1/421 |
All randomized participants.
| Age, Continuous(years) | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil | Total |
|---|---|---|---|
| Mean | 42.6 ± 11.11 | 44.1 ± 10.90 | 43.6 ± 10.98 |
| Sex: Female, Male(Participants) | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 211 | 424 | 635 |
| Race (NIH/OMB)(Participants) | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 211 | 424 | 635 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 2.5 mg/5 mg Tadalafil | 5 mg Tadalafil | Total |
|---|---|---|---|
| China | 211 | 424 | 635 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Oct 2014, a primary completion of May 2016 and a completion of May 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil